StockData

Spyre Therapeutics, Inc. (SYRE) stock

SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$101.46+7.65 (+8.15%)

Close on Nov 18, 2026Market cap $8.95BP/E –Yield –

Spyre Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Spyre Therapeutics's price to sales ratio was 99.5× on Jan 31, 2024, against 5.3× a year earlier. Over the last 4 years it ranged from 1.0× to 108.7×, with a median of 30.7×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2024Jan 31, 202499.5×+16.9
2023Dec 29, 202382.7×+77.9
2022Dec 30, 20224.8×−103.9
2019Jul 31, 2019108.7×+77.8
2018Dec 31, 201830.8×–

More Spyre Therapeutics figures

See a number that looks wrong?